Evidence map›Paper›PMID 34885155›Full record

ArticleCancers2021

Performance Evaluation for Repair of HSGc-C5 Carcinoma Cell Using Geant4-DNA.

Dousatsu Sakata, Masao Suzuki, Ryoichi Hirayama, Yasushi Abe, Masayuki Muramatsu, Shinji Sato, Oleg Belov, Ioanna Kyriakou, Dimitris Emfietzoglou, Susanna Guatelli and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Dousatsu SakataDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.ORCID 0000-0002-8398-3334
Masao SuzukiDepartment of Charged Particle Therapy Research, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.
Ryoichi HirayamaDepartment of Charged Particle Therapy Research, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.
Yasushi AbeDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.
Masayuki MuramatsuDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.
Shinji SatoDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.
Oleg BelovVeksler and Baldin Laboratory of High Energy Physics, Joint Institute for Nuclear Research, 141980 Dubna, Russia.ORCID 0000-0002-9429-3793
Ioanna KyriakouMedical Physics Laboratory, Medical School, University of Ioannina, 45110 Ioannina, Greece.
Dimitris EmfietzoglouMedical Physics Laboratory, Medical School, University of Ioannina, 45110 Ioannina, Greece.
Susanna GuatelliCentre For Medical Radiation Physics, University of Wollongong, Wollongong 2522, Australia.
Sebastien IncertiCentre d'Études Nucléaires de Bordeaux Gradignan, CNRS/IN2P3, UMR5797, Université de Bordeaux, F-33170 Gradignan, France.ORCID 0000-0002-0619-2053
Taku InaniwaDepartment of Accelerator and Medical Physics, Institute for Quantum Medical Science, QST, Chiba 263-8555, Japan.
National Institutes for Quantum Science and Technology · JPUniversity of Ioannina · GRCentre National de la Recherche Scientifique · FRJoint Institute for Nuclear Research · RUUniversity of Wollongong · AU

Funding

JSPS KAKENHI JP20K16840QST President's Strategic Grant Creative Research
6 · The paper itself

Abstract

Track-structure Monte Carlo simulations are useful tools to evaluate initial DNA damage induced by irradiation. In the previous study, we have developed a Gean4-DNA-based application to estimate the cell surviving fraction of V79 cells after irradiation, bridging the gap between the initial DNA damage and the DNA rejoining kinetics by means of the two-lesion kinetics (TLK) model. However, since the DNA repair performance depends on cell line, the same model parameters cannot be used for different cell lines. Thus, we extended the Geant4-DNA application with a TLK model for the evaluation of DNA damage repair performance in HSGc-C5 carcinoma cells which are typically used for evaluating proton/carbon radiation treatment effects. For this evaluation, we also performed experimental measurements for cell surviving fractions and DNA rejoining kinetics of the HSGc-C5 cells irradiated by 70 MeV protons at the cyclotron facility at the National Institutes for Quantum and Radiological Science and Technology (QST). Concerning fast- and slow-DNA rejoining, the TLK model parameters were adequately optimized with the simulated initial DNA damage. The optimized DNA rejoining speeds were reasonably agreed with the experimental DNA rejoining speeds. Using the optimized TLK model, the Geant4-DNA simulation is now able to predict cell survival and DNA-rejoining kinetics for HSGc-C5 cells.

Indexed as

cell surviving fractionDNA repairGeant4-DNA

Identifiers

PMID34885155
PMCPMC8656964
OpenAlexW3216299189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.